drugset / Trial / NCT00539448
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus. Secondary objective : * Recording the average daily dose of both insulin Glulisine \& insulin Glargine in type I DM. * Recording adverse events.
Timeline
- Start
- 2007-04
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin glulisine | Protein / enzyme biologic | — | — |
| Subject | insulin glargine | Protein / enzyme biologic | — | — |